Skip to main content

ESTUDIO DE TAS1R3 COMO BIOMARCADOR DE CELULAS MADRE TUMORALES Y DE APLICACION PARA EL DESARROLLO DE NUEVAS ESTRATEGIAS TERAPEUTICAS HACIENDO USO DE LA NANOTECNOLOGIA

PI18/00176

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2018
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA
Execution centre INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA (IDIS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Modulation of colorectal tumor behavior via lncRNA TP53TG1-lipidic nanosystem

  • Masoumi, Farimah
  • Saraiva, Sofia M.
  • Bouzo, Belén L.
  • López-López, Rafael|||0000-0002-2240-6277
  • Esteller, M|||0000-0003-4490-6093
  • Diaz-Lagares, Angel|||0000-0002-9114-9227
  • de la Fuente, María
Long non-coding RNAs (lncRNAs) are an emerging group of RNAs with a crucial role in cancer pathogenesis. In gastrointestinal cancers, TP53 target 1 (TP53TG1) is an epigenetically regulated lncRNA that represents a promising therapeutic target due to its tumor suppressor properties regulating the p53-mediated DNA damage and the intracellular localization of the oncogenic YBX1 protein. However, to translate this finding into the clinic as a gene therapy, it is important to develop effective carriers able to deliver exogenous lncRNAs to the targeted cancer cells. Here, we propose the use of biocompatible sphingomyelin nanosystems comprising DOTAP (DSNs) to carry and deliver a plasmid vector encoding for TP53TG1 (pc(TP53TG1)-DSNs) to a colorectal cancer cell line (HCT-116). DSNs presented a high association capacity and convenient physicochemical properties. In addition, pc(TP53TG1)-DSNs showed anti-tumor activities in vitro, specifically a decrease in the proliferation rate, a diminished colony-forming capacity, and hampered migration and invasiveness of the treated cancer cells. Consequently, the proposed strategy displays a high potential as a therapeutic approach for colorectal cancer.